Summary Formoterol is a long-acting b 2 -agonist with a rapid onset of effect in patients with chronic obstructive pulmonary disease (COPD), making it potentially suitable for both maintenance and as-needed bronchodilator treatment.
Introduction
Inhaled bronchodilators (anticholinergics and b 2 -agonists) are central to the symptomatic management of chronic obstructive pulmonary disease (COPD). The overall goals of maintenance bronchodilator treatment are to induce bronchodilation, facilitate expectoration and reduce symptoms, as well as enhancing health status.
1,2 Long-acting b 2 -agonists, such as formoterol and salmeterol, have a duration of action of at least 12 h 3, 4 and are suitable for regular maintenance therapy in patients with COPD. 1 Maintenance formoterol therapy was evaluated in a 3-month, placebo-controlled study, performed in 692 patients with COPD showing poorly reversible bronchoconstriction. The study showed that formoterol 9 and 18 mg twice-daily (bid) via Turbuhaler s were well tolerated, improved lung function and reduced daily symptoms of breathlessness. 5 Other clinical studies in COPD have also shown that regular maintenance treatment with long-acting b 2 -agonists enhance health status as effectively if not better than as-needed short-acting b 2 -agonists, anticholinergics, or placebo. [6] [7] [8] [9] An additional benefit of long-acting b 2 -agonists is a reduction in the need for relief medication to control breakthrough symptoms, although relief medication is still normally required on a daily basis. 4, 5 Formoterol is a unique b 2 -agonist with both a rapid onset of effect, similar to salbutamol, 10, 11 and a long duration of action, similar to salmeterol. 12 Formoterol may therefore be suitable for both maintenance and as-needed treatment in COPD.
The primary objective of this 6-month study was to provide additional evidence for the long-term efficacy and safety of formoterol 9 mg bid via Turbuhaler s . Previous studies have examined formoterol in COPD for only 3 months. 5, 6, 9 A novel feature of the study design was the inclusion of a 3-week placebo washout period; this permitted detection of any loss of efficacy or rebound increases in symptoms after withdrawal of formoterol, to further validate the study findings. As patients were required to use separate reliever medication, a secondary objective of the study was to evaluate the safety and efficacy of using additional, as-needed formoterol compared with terbutaline as needed.
Methods
A randomized, double-blind, placebo-controlled, parallel-group study conducted in 73 centers in eight countries (Bulgaria, Hungary, Israel, The Netherlands, Romania, Spain, Sweden, and the UK).
Patients
Patients X40 years of age with a clinical diagnosis of COPD were eligible if they met the inclusion criteria: symptoms X2 years; pre-bronchodilator forced expiratory volume in 1 s (FEV 1 ) 40-70% predicted normal 13 and FEV 1 /slow vital capacity (slow VC) o70%; current or previous smokers with a history of smoking of X10 pack-years. Patients were excluded from the study if they had disease onset before 40 years of age with any history of asthma or seasonal allergic rhinitis; had changed their dose of inhaled corticosteroids, used either oral steroids or had experienced a significant exacerbation of COPD within the last month; had any disorder that might, in the investigator's opinion, put them at risk (including significant or unstable cardiovascular disorder); had a requirement for domiciliary oxygen; or were females of child bearing potential.
All patients gave written informed consent and the study was approved by an independent Ethical Committee in all centers.
Study design
At visit 1 (À3 weeks), eligible patients entered a 3-week, open, run-in period during which they received as-needed terbutaline 0.5 mg for symptom relief. Providing that their combined symptom ARTICLE IN PRESS score (CSS) (total score 0-8 per day) was X2 on at least 10 days of the run-in period, patients were randomized at visit 2 (time 0) to receive 6 months of treatment with either: formoterol (Oxis s ) 9 mg bid plus as-needed terbutaline (Bricanyl s ) 0.5 mg (FORM bid); formoterol 9 mg bid plus as-needed formoterol 4.5 mg (FORM bid+prn); or placebo plus as-needed terbutaline 0.5 mg (placebo), all via the dry powder inhaler Turbuhaler s . Treatment was randomized in balanced blocks using a computergenerated scheme provided in coded envelopes. The double-blind treatment period was followed by a 3-week, single-blind placebo washout, during which all treatment groups received placebo bid plus as-needed terbutaline, to evaluate the effect of withdrawal of formoterol treatment.
Patients were allowed to use inhaled and nasal corticosteroids, without modification of dosage or frequency of administration, throughout the study. Disodium cromoglycate, ephedrine, antihistamines, beta-blockers, and bronchodilators other than study medication were not allowed during the study. No limit on the daily number of rescue inhalations of formoterol or terbutaline was specified.
Reversibility to both formoterol 9 mg and terbutaline 0.5 mg was assessed in a random crossover design at visits 1 and 2, by measuring FEV 1 pre-and 15 min post-bronchodilator.
Variables
The two primary efficacy variables were FEV 1 and CSS. Secondary variables included morning peak expiratory flow (PEF), slow VC, symptoms of COPD (including breathlessness, chest tightness, cough, and sleep disturbance), as-needed medication use, time to first severe exacerbation, and healthrelated quality of life (HRQL).
FEV 1 and slow VC were measured at clinic visits and the highest value from three technically satisfactory maneuvers was recorded. Patients took their regular study drug at home 30 min to 2 h before the lung function tests and refrained from using rescue medication for 6 h before lung function tests. COPD symptoms (breathlessness, chest tightness, cough, and sleep disturbance), morning PEF, and both regular study and as-needed medication use were recorded daily on electronic diary cards, which dated and time-stamped all entries and prevented retrospective data entry. Patients assessed the intensity of individual COPD symptoms on a scale of 0-4 per day (0 ¼ no symptoms, 4 ¼ severe symptoms). CSS was defined as the sum of breathlessness and chest tightness scores thus the CSS score ranged from 0 to 8. Morning PEF was measured with a MiniWright s peak flow meter on waking, before taking the first dose of study medication and preferably 46 h after the last dose of rescue medication.
HRQL was recorded using the St. George's Respiratory Questionnaire (SGRQ).
14 This questionnaire assesses HRQL in three domains: Symptoms (distress due to respiratory symptoms), Activity (disturbance of physical activity), and Impacts (overall impact on daily life and well-being). Questionnaires were completed, before any other study-related procedures, in the patient's own language during visits 2, 3 (2 months), 5 (6 months), and 6 (end of washout period). Severe COPD exacerbations, defined as the need for oral steroids, change in dose of inhaled corticosteroids, or need for antibiotics or hospitalization, were recorded at the clinic visits.
Adverse events (AEs) were identified by means of a standard question at each clinic visit and from patient diary data. Standard clinical-chemical measurements (including serum glucose and serum potassium levels), blood pressure measurements and electrocardiogram (ECG) assessments were made at visits 1 and 5.
Statistical analysis
An intention-to-treat approach was used throughout. With 200 patients per treatment group, assuming a standard deviation of 0.20 log units for FEV 1 and 1 point for CSS, there was a 90% chance of detecting a true difference of 0.06 log units (i.e. a relative difference of 6.0%) and 0.32 points for FEV 1 and CSS, respectively, at the 5% significance level using a two-sided test.
For spirometry variables, values at visits 2 and 6 constituted the run-in and follow-up period values, respectively, and the average over visits 4 (4 months) and 5-the treatment period value. Period means for diary data were computed over the run-in period, the last 90 days of the treatment period, and over the follow-up period.
Most variables were compared between treatments using an analysis of variance model with treatment and country as factors, and baseline as a covariate. When analyzing the treatment period, the run-in values constituted baseline and when analyzing the follow-up data, the treatment period values constituted baseline. For SGRQ data, values from each visit were analyzed separately. Time-toevent variables were described using Kaplan-Meier plots and compared between treatment groups by the log-rank test (withdrawals) or a Cox proportional hazards model (severe exacerbations).
For the two primary efficacy variables, subgroup analyses were performed, stratifying patients by use of inhaled corticosteroids (yes vs. no), smoking habit (current vs. ex-smoker), and FEV 1 reversibility (below vs. above median reversibility expressed as % predicted normal) at visit 1.
Results
The first patient entered the study in July 2000, the last patient completed randomized treatment in October 2001 and the last patient completed follow-up in November 2001. Of the 906 patients enrolled, 657 were randomized to treatment. Of the 249 patients not randomized, 218 did not meet eligibility criteria, 30 patients were withdrawn because of AEs, and one patient was lost to follow-up. Ninety-eight patients were withdrawn during randomized treatment (FORM bid: n ¼ 30; FORM bid+prn: n ¼ 29; placebo: n ¼ 39), 31 patients were withdrawn due to AEs, three were lost to follow-up, 23 due to eligibility criteria, and 41 due to other reasons. Two patients were withdrawn during the follow-up period: one due to an AE (FORM bid) and one because of other reasons (FORM bid+prn). There was no statistically significant difference in withdrawal rates between groups during the treatment period (P ¼ 0:109).
Demographic and other patient characteristics were generally well balanced across the treatment groups (Table 1 ). Reversibility testing in 606 patients at visits 1 and 2 gave similar increases from baseline in FEV 1 with terbutaline (8.9%) and formoterol (9.9%; P ¼ 0:133). The median reversibility at visit 1 was 3.78% predicted normal.
Lung function
FORM bid and FORM bid+prn significantly increased FEV 1 compared with placebo (Po0:01 and (o3.78% predicted) FEV 1 increased by 5.9% (95% CI: 0.5, 11.6%; Po0:05) in the FORM bid group and by 14.7% (95% CI: 8.9, 20.7%; Po0:001) in the FORM bid+prn group compared with placebo. In the higher reversibility group (43.78% predicted) FEV 1 increased by 7.4% (95% CI: 1.6, 13.4%; Po0:05) in the FORM bid group and by 8.2% (95% CI: 2.4, 14.4%; Po0:01) in the FORM bid+prn group compared with placebo.
ARTICLE IN PRESS
Both formoterol groups increased pre-treatment morning PEF and slow VC vs. placebo, but there were no significant differences between the FORM bid+prn and FORM bid groups (Table 2 and Fig. 1b ).
Symptoms and reliever use
The mean decreases from baseline in CSS were significantly greater for FORM bid (Po0:05) and FORM bid+prn (Po0:01) than in the placebo group (Table 2 ). There was no significant difference in CSS between the formoterol treatment groups. Furthermore, smoking status, use of concomitant inhaled corticosteroids and reversibility at entry had no effect on CSS.
When individual COPD symptom scores were examined, a similar pattern was observed with significant (Po0:05) differences for breathlessness, chest tightness, cough, and sleep disturbance for both formoterol groups compared with placebo ( Fig. 2) . Improvements in individual symptom scores were not statistically significantly different between the formoterol groups.
The mean use of as-needed medication decreased progressively during treatment in both formoterol groups (Fig. 3) . The total daily number of inhalations taken ( 
Severe exacerbations
In total, 92 patients experienced at least one severe exacerbation of COPD during the study (FORM bid+prn: n ¼ 23; FORM bid: n ¼ 35; placebo: n ¼ 34). There was no difference between the FORM bid and placebo groups (HR: 
Health-related quality of life
Large improvements were noted in HRQL throughout the 6-month study period in each treatment group, including the placebo group (Fig. 4 and Table 2 ). No treatment differences were apparent between the FORM bid and placebo groups at visits 3 or 5. Significant treatment differences were seen at visit 5 
Efficacy on treatment withdrawal
Within 3 weeks of withdrawal of formoterol, FEV 1 and slow VC recordings approached baseline values in both formoterol groups. These decreases in FEV 1 and slow VC were significant in both the FORM bid group (Po0:001 and Po0:01, respectively) and the FORM bid+prn group (both Po0:001) relative to placebo (Table 3) . Furthermore, compared with the placebo group, withdrawal of formoterol resulted in a significant (Po0:001) decline in PEF in both formoterol groups (Table 3 ). The loss of improvement in PEF in the FORM bid+prn group was greater than in the FORM bid group (Po0:05; Table 3 
Tolerability
The frequency of AEs throughout the study was low (FORM bid 3.8 events, FORM bid+prn 3.0 events, placebo 4.5 events) per 1000 treatment days. The only AEs with an incidence in X3% of patients in any group were respiratory infections and pharyngitis. Undesirable class effects of b 2 -agonists (palpitations, cramps, tremor) were reported in o1% of patients in all groups. Abnormal cardiovascular events, including ECG abnormalities, were also reported with a similar incidence in all groups.
There was a similar incidence of serious AEs (SAEs) in each of the treatment groups (FORM bid: n ¼ 13, FORM bid+prn: n ¼ 7, placebo: n ¼ 9). This included three deaths in male patients (68-75 years old), two in the FORM bid group and one in the FORM bid+prn group, but were considered unrelated to study treatment. SAEs were mainly related to the patients' underlying disease. Thirty-one patients discontinued due to AEs during the treatment period: (FORM bid+prn: n ¼ 8, FORM bid: n ¼ 13, placebo: n ¼ 10). One patient in the FORM bid group discontinued due to an AE during followup. No safety concerns arose from laboratory measurements, vital signs, or ECG. The number of laboratory abnormalities/changes emerging during the treatment period was similar in all groups.
Discussion
This 6-month study demonstrates the benefits of regular treatment with formoterol 9 mg bid via Turbuhaler s in the management of COPD. Furthermore, these benefits were seen independent of patients' initial response to a single dose of b 2 -agonist. Additional doses of formoterol were also shown to be as effective as terbutaline for asneeded symptom relief. Consistent and significant improvements were seen in both formoterol groups for all lung function parameters (FEV 1 , morning PEF, and slow VC) and all COPD symptom scores (breathlessness, chest tightness, cough, and sleep disturbances) measured. These effects on lung function, symptom scores and reliever use were maintained throughout the study period in both formoterol groups, with no clinical signs of decreasing bronchodilator effects indicative of tachyphylaxis.
ARTICLE IN PRESS
There was a larger improvement in FEV 1 with formoterol 4.5 mg as needed compared with terbutaline 0.5 mg as needed in addition to maintenance formoterol treatment, though this increase in efficacy with as-needed formoterol was not observed for the other primary variable (CSS). This indicates that some patients benefit more from using formoterol as needed than terbutaline as needed, on top of regular formoterol treatment 9 mg bid. This may be as a result of formoterol's longer duration of bronchodilation compared with that of terbutaline.
In mild-to-moderate persistent asthma, the benefits of maintenance or as-needed formoterol include a reduction in severe exacerbations. [15] [16] [17] The efficacy of formoterol in the treatment of acute asthma and COPD exacerbations has also been demonstrated. [18] [19] [20] However, in the present study, maintenance formoterol with terbutaline as reliever had no effect on the prevention of COPD exacerbations. The trend for a reduction in the relative risk of COPD exacerbations with formoterol as both maintenance and as-needed therapy compared with formoterol maintenance treatment alone, could be a chance finding, but may warrant further investigation.
Another surprising result was the clinically significant (44 unit decrease) 8 improvement in total SGRQ score that occurred in the placebo arm in this study. In two previous studies, formoterol 12 mg metered dose bid via Aerolizer s , and 9 mg bid via Turbuhaler s , both enhanced patients' health status over 3-12 months with no improvements seen with placebo 6, 21 ; indicating that detection of any improvement in patients' wellbeing with formoterol was possibly impaired in this study due to a marked placebo response during the initial 6 months of treatment.
A novel aspect of this study design was the inclusion of a 3-week, single-blind, washout period, in which all patients received placebo bid plus terbutaline as-needed. Most of the improvements in efficacy measures obtained during the treatment period were lost after cessation of formoterol treatment, although no rebound increases in symptoms or deteriorations in lung function or health status were observed compared with baseline. Notably, following the washout period, total SGRQ scores worsened in both formoterol groups, particularly in the symptom domain, upon replacement with placebo plus terbutaline as needed. Thus, the benefits provided by formoterol with regard to health status were apparent within 3 weeks of treatment withdrawal, but not during the initial 6-month treatment phase. The largest improvements in FEV 1 were seen with maintenance plus as-needed formoterol treatment, particularly in patients who showed lower vs. higher reversibility to a single dose of terbutaline or formoterol at study entry. This supports previous assertions (reviewed by Mahler) 2 that a single reversibility test is not predictive of long-term outcomes with b 2 -agonists in patients with COPD; indicating that long-term treatment with formoterol may be equally effective in patients with low or high reversibility. Indeed, Muir et al. 22 conclude that formoterol is effective in patients with COPD irrespective of their response to reversibility testing.
Formoterol was well tolerated when used for maintenance therapy together with either formoterol or terbutaline as needed. No safety concerns with formoterol were identified within the study, as measured by AEs, SAEs, discontinuations due to AEs, and number of COPD exacerbations. AEs were generally mild and as would be expected from the population of patients studied. There were very few b 2 -agonist class-related AEs, and none of these were serious. High doses of formoterol are well tolerated in asthma and COPD patients. [23] [24] [25] A recent study in patients with COPD 25 showed that salbutamol and formoterol were equally effective and well tolerated when given acutely as 10 cumulative doses; extra-pulmonary side effects of high doses of both inhaled formoterol (total dose 90 mg) and salbutamol (total dose 2 mg) were low and without obvious clinical significance.
Cardiovascular AEs are of most concern for the safe use of b 2 -agonists in COPD. Although this study specifically excluded patients with severe cardiovascular disease, it did not identify any clinically important changes in ECG variables, vital signs, or any other cardiovascular issues during the study. Incidences of cardiovascular abnormalities were as expected for the population studied, and there were no differences between treatments. The favorable cardiovascular tolerability demonstrated in both formoterol groups in this study is supported by results from a 1-year study of the use of formoterol in COPD, in which ECG and cardiovascular events were examined during administration of formoterol (24 mg bid; metered dose). 21 An obvious benefit of using formoterol both for as-needed and maintenance use may be improved convenience for patients, by reducing the number of inhalers required for effective bronchodilator therapy. Multiple inhalers can introduce unnecessary complexity, which is undesirable because of the adverse effect this can have on patient adherence. 26 In the present study, a single inhaler for both maintenance and relief was not an option, because of the need to double-blind both maintenance and reliever therapy, although this simplified treatment approach warrants further investigation in a long-term effectiveness study.
In conclusion, the present study demonstrates that formoterol 9 mg bid via Turbuhaler s is an effective and well-tolerated maintenance treatment for patients with COPD, providing sustained improvements in lung function and COPD symptoms over 6 months. These benefits were seen irrespective of patients' initial response to a single test dose of b 2 -agonist. The use of as-needed formoterol, as an alternative to as-needed terbutaline on top of maintenance formoterol treatment, was also well tolerated and provided some additional improvements in lung function.
